Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 1, 2012, Pages 99-110

  Homans, James ^a   Christensen, Shawna ^a   Stiller, Tracey ^b   Wang, Chia Hao ^a   MacK, Wendy ^a   Anastos, Kathryn ^c   Minkoff, Howard ^d   Young, Mary ^e   Greenblatt, Ruth ^f   Cohen, Mardge ^g   Strickler, Howard ^c   Karim, Roksana ^a   Spencer, Lashonda Yvette ^a   Operskalski, Eva ^a   Frederick, Toinette ^a   Kovacs, Andrea ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MAIMONIDES MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g RUSH MEDICAL COLLEGE   (United States)

Author keywords

Antiretroviral therapy; Cervicovaginal; HIV 1; Inflammation; Plasma viral load; Shedding

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; FEMALE; HERPES SIMPLEX VIRUS 2; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TRICHOMONIASIS; UTERINE CERVIX DISEASE; VIRUS LOAD; VIRUS SHEDDING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CERVIX UTERI; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; VAGINA; VIRAL LOAD; VIRUS SHEDDING;

EID: 84862124856     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824aeaaa     Document Type: Article

References (45)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2009. AIDS Epidemic Update: December 2009. Geneva, Switzerland: UNAIDS; 2009.
2. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med. 2011;365:493-505.
3. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929. (Pubitemid 30177052)
4. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-tochild human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis. 2001;183:206-212. (Pubitemid 32066020)
5. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
6. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3:77 ra29.
7. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358:1593-1601. (Pubitemid 33101909)
8. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS. 1997;11: F85-F93. (Pubitemid 27421168)
9. Kreiss J, Willerford DM, Hensel M, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis. 1994;170:1597-1601. (Pubitemid 24369926)
10. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS. 2007;21:501-507.
11. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS. 2003;17:2169-2176. (Pubitemid 37338890)
12. Kemal KS, Foley B, Burger H, et al. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A. 2003;100:12972-12977. (Pubitemid 37340010)
13. Tirado G, Jove G, Kumar R, et al. Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female. AIDS Res Hum Retroviruses. 2004;20:684-686. (Pubitemid 38813668)
14. Delwart EL, Mullins JI, Gupta P, et al. Human immunodeficiency virus type 1 populations in blood and semen. J Virol. 1998;72:617-623. (Pubitemid 28048879)
15. Petito CK. Human immunodeficiency virus type 1 compartmentalization in the central nervous system. J Neurovirol. 2004;10(suppl 1):21-24. (Pubitemid 38325089)
16. Smit TK, Brew BJ, Tourtellotte W, et al. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol. 2004;78:10133-10148. (Pubitemid 39187131)
17. Ellerbrock TV, Lennox JL, Clancy KA, et al. Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis. 2001;184:28-36. (Pubitemid 32568497)
18. Wright TC Jr, Subbarao S, Ellerbrock TV, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol. 2001;184: 279-285. (Pubitemid 32206972)
19. Sha BE, Zariffard MR, Wang QJ, et al. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis. 2005;191:25-32. (Pubitemid 40041396)
20. Tanton C, Weiss HA, Le GJ, et al. Correlates of HIV-1 genital shedding in Tanzanian women. PLoS ONE. 2011;6:e17480.
21. Spinillo A, Zara F, Gardella B, et al. The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions. Am J Obstet Gynecol. 2005;192:774-779. (Pubitemid 40311269)
22. Legoff J, Weiss HA, Gresenguet G, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS. 2007;21:1569-1578. (Pubitemid 47075478)
23. Al-Harthi L, Kovacs A, Coombs RW, et al. A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS. 2001;15:1535-1543. (Pubitemid 32744601)
24. Reichelderfer PS, Coombs RW, Wright DJ, et al. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS. 2000;14:2101-2107.
25. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12:19-26.
26. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14: 415-421. (Pubitemid 30182438)
27. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44:38-42. (Pubitemid 46052218)
28. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS. 2010;24:2489-2497.
29. Kwara A, DeLong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving longterm highly active antiretroviral therapy. Clin Infect Dis. 2008;46: 719-725. (Pubitemid 351321556)
30. Coombs RW, Wright DJ, Reichelderfer PS, et al. Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: implications for applying measurements to individual women. J Infect Dis. 2001;184:1187-1191. (Pubitemid 33010473)
31. Villanueva JM, Ellerbrock TV, Lennox JL, et al. The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions. J Infect Dis. 2002;185:170-177. (Pubitemid 34056440)
32. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125. (Pubitemid 28157608)
33. Landay A, Benning L, Bremer J, et al. Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis. 2003;188:209-218. (Pubitemid 36898152)
34. Operskalski EA, Mack WJ, Strickler HD, et al. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and-uninfected women. J Clin Virol. 2008;41:255-263.
35. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
36. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999;91: 226-236. (Pubitemid 29090991)
37. DHHS Panel on Antiretroviral Guidelines for Adultsand Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSInfo. March 2011:1-139.
38. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr. 2006;42:584-587. (Pubitemid 44162427)
39. Lawn SD, Subbarao S, Wright TC Jr, et al. Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix. J Infect Dis. 2000;181:1950-1956. (Pubitemid 30416156)
40. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis. 2009;36:11-16.
41. Theall KP, Amedee A, Clark RA, et al. Alcohol consumption and HIV-1 vaginal RNA shedding among women. J Stud Alcohol Drugs. 2008;69: 454-458.
42. Poonia B, Nelson S, Bagby GJ, et al. Chronic alcohol consumption results in higher simian immunodeficiency virus replication in mucosally inoculated rhesus macaques. AIDS Res Hum Retroviruses. 2006;22: 589-594.
43. Bagasra O, Whittle P, Kajdacsy-Balla A, et al. Effects of alcohol ingestion on in vitro susceptibility of peripheral blood mononuclear cells to infection with HIV-1 and on CD4 and CD8 lymphocytes. Prog Clin Biol Res. 1990;325:351-358.
44. Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis. 2008;198:241-249. (Pubitemid 352035760)
45. Vernazza P, Hirschel B, Bernasconi E, et al. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bulletin des Médecins Suisses. 2008;89:165-169.